Metraipolis › archive › dc_d63a6523bf79

Immunogenicity and safety of a single dose of adjuvanted RSVPreF3 vaccine in adults ≥60 years of age in China: results from a phase 3 immunobridging trial — Europe PMC PMID:42756146

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42756146
DOI
10.3389/fimmu.2026.1894773
License (as archived)
solo-consultazione
Archived
2026-10-16T03:52:52.862Z
SHA-256 of the archived text
1621f44d397ea9d77224e1e54d4920885ffe46651d15860c08836fbe61978686
Stable URL of this page
https://metraipolis.com/documento/dc_d63a6523bf79

How to cite

Immunogenicity and safety of a single dose of adjuvanted RSVPreF3 vaccine in adults ≥60 years of age in China: results from a phase 3 immunobridging trial — Europe PMC PMID:42756146 — Europe PMC (en), https://europepmc.org/article/MED/42756146 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d63a6523bf79 (Metraipolis archive dc_d63a6523bf79, sha256 1621f44d397ea9d77224e1e54d4920885ffe46651d15860c08836fbe61978686)
BibTeX
@misc{dcd63a6523bf79,
  title = {Immunogenicity and safety of a single dose of adjuvanted RSVPreF3 vaccine in adults ≥60 years of age in China: results from a phase 3 immunobridging trial — Europe PMC PMID:42756146},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42756146},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d63a6523bf79; sha256 1621f44d397ea9d77224e1e54d4920885ffe46651d15860c08836fbe61978686},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42756146. Agents can read the archived copy with the MCP tool read_document.